follows a period of significant growth for Dunbar Pharma, which was recently named Emerging Company of the Year at the 2026 BioPharmaChem Impact Awards, recognising the company's innovation and leadership in pharmaceutical manufacturing. WaterClear...
laboratory at Chemspeed’s headquarters near Basel, Switzerland. Atinary’s Self-Driving Lab in Boston opened in early 2026 as a Scientific Data Factory to bring better molecules and products to market faster. The Atinary Lab includes Chemspeed...
RSV season. The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date of March 22, 2027. In July 2026, the European Medicines Agency (EMA) accepted the application to expand marketing authorization for ENFLONSIA in the...
of the new drug application for oveporexton to the U.S. FDA, please refer to Takeda’s press release dated February 10, 2026, “U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton...
100 mg/mL of Merck Sharp & Dohme LLC [NDA 022225]. According to IQVIA® sales data for the 12-month period ending May 2026, the BRIDION® Injection, 100 mg/mL market3 achieved annual sales of approximately $1.6 billion*. Commenting on the launch,...
capabilities and advancing additional clinical validation studies. August 3 Global Product Launch On August 3, 2026, InstaMed® will launch five next-generation oral dissolving peptide products, further expanding its biotechnology platform. The...
collaboration capabilities. Ciprocopan Succinate Tablets is also a key program in Haisco's globalization strategy. In June 2026, Haisco entered into an Exclusive License Agreement with U.S.-based Nuvectis Pharma, Inc., granting Nuvectis exclusive...
Pharmacy Education 2026 is your chance to grow, learn, and lead. Don’t miss the professional development event everyone will be talking about—join us in Grapevine, Texas, July 18-21, for bold ideas, powerful connections, and real-world impact....
today published a shareholder update from Chief Executive Officer James Foster providing context on the Company's fiscal 2026 Annual Report and subsequent commercial, financing and Nasdaq compliance developments. The Annual Report provides audited...
company, announced that the European Commission (EC) approved an update to the Erbitux (cetuximab) EU label on June 26, 2026. Erbitux is now indicated in combination with encorafenib for patients with BRAF V600E-mutant metastatic colorectal cancer...
On July 2, 2026, the U.S. Food and Drug Administration (FDA) approved the use of wilate® (von Willebrand Factor/Coagulation Factor VIII Complex [Human]) for routine prophylaxis to reduce the frequency of bleeding episodes in pediatric patients...
NN Conference is a world-class International event in Nanosciences and Nanotechnologies (N&N) that focuses on the latest advances on N&N and promotes profound scientific discussions between scientists, researchers from different disciplines and...
medication management, announced that Nnamdi Njoku has been appointed President of the Company, effective July 1, 2026. Mr. Njoku will retain his role of Chief Operating Officer (COO), while Randall Lipps will continue to serve as Chief Executive...
for all strengths of Wegovy® pill includes Novo Nordisk Inc. partner-reported paid claims only from January 5, 2026 through June 2, 2026. †Terms apply. For eligible Medicare patients prescribed Wegovy® for a covered FDA-approved indication....
standards. U.S. sales of Bortezomib for Injection were approximately $43 million for the twelve months ending in March 2026.¹ Indications Bortezomib for Injection is indicated for the treatment of adult patients with multiple myeloma and mantle...
made via fermentation. The expansion follows a period of rapid commercial growth for EVERY: in the first four months of 2026, the company secured annual orders worth 550% of its total 2025 order volume. This surge is driven by strong adoption...
These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 -...
The DIA 2026 Global Annual Meeting is evolving, just like the life sciences community it serves. Join global innovators, regulators, academics, patient advocates, and industry leaders for an all-new experience designed to inspire, engage, and...
AbbVie announced new Phase 3 data on a fixed-duration venetoclax-based combination. Final results from the Phase 3 CLL14 trial in previously untreated chronic lymphocytic leukemia (CLL), which was conducted in collaboration with the German CLL...
mean Hgb improvement of at least 1g/dL as early as Week 1.1,c To be presented at the European Hematology Association (EHA) 2026 Congress, these results mark an important step forward for people living with wAIHA, a rare, life-threatening condition...
